75 related articles for article (PubMed ID: 7893861)
1. The effects of central cholecystokinin receptor blockade on hypothalamic-pituitary-adrenal and symptomatic responses to overnight withdrawal from alprazolam.
Abelson JL; Curtis GC; Nesse R; Fantone R; Pyke RE; Bammert-Adams J
Biol Psychiatry; 1995 Jan; 37(1):56-9. PubMed ID: 7893861
[No Abstract] [Full Text] [Related]
2. Attenuation of the hypothalamic-pituitary-adrenal axis responsivity to the Trier Social Stress Test by the benzodiazepine alprazolam.
Fries E; Hellhammer DH; Hellhammer J
Psychoneuroendocrinology; 2006 Nov; 31(10):1278-88. PubMed ID: 17097811
[TBL] [Abstract][Full Text] [Related]
3. Centrally administered PD 140.548 N-methyl-D-glucamine prevents the autonomic responses to duodenal pain in sheep.
Kania BF; Kania K; Romanowicz K; Tomaszewska D; Sutiak V; Wronska-Fortuna D
Res Vet Sci; 2006 Aug; 81(1):109-18. PubMed ID: 16375934
[TBL] [Abstract][Full Text] [Related]
4. Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers.
Bradwejn J; Koszycki D; Paradis M; Reece P; Hinton J; Sedman A
Biol Psychiatry; 1995 Dec; 38(11):742-6. PubMed ID: 8580227
[TBL] [Abstract][Full Text] [Related]
5. Single-site findings in a study of the safety and efficacy of a CCKB receptor antagonist, CI-988, in the treatment of generalized anxiety disorder.
Sramek JJ; Costa JF; Adams JB; Macpherson A; Cutler NR
Anxiety; 1994-1995; 1(5):242-3. PubMed ID: 9160582
[No Abstract] [Full Text] [Related]
6. [Cholecystokinin receptor antagonists].
Ohtsuka T; Yokose K
Tanpakushitsu Kakusan Koso; 1993 Aug; 38(11):1853-62. PubMed ID: 8210429
[No Abstract] [Full Text] [Related]
7. Impaired hypothalamic-pituitary-adrenocortical (HPA) system is related to severity of benzodiazepine withdrawal in patients with depression.
Wichniak A; Brunner H; Ising M; Pedrosa Gil F; Holsboer F; Friess E
Psychoneuroendocrinology; 2004 Oct; 29(9):1101-8. PubMed ID: 15219633
[TBL] [Abstract][Full Text] [Related]
8. The antagonism of benzodiazepine withdrawal effects by the selective cholecystokininB receptor antagonist CI-988.
Singh L; Field MJ; Vass CA; Hughes J; Woodruff GN
Br J Pharmacol; 1992 Jan; 105(1):8-10. PubMed ID: 1350747
[TBL] [Abstract][Full Text] [Related]
9. Effect of CI-988, a cholecystokinin-B receptor antagonist, on lactate-induced panic.
Cowley DS; Adams JB; Pyke RE; Cook J; Zaccharias P; Wingerson D; Roy-Byrne PP
Biol Psychiatry; 1996 Sep; 40(6):550-2. PubMed ID: 8879478
[No Abstract] [Full Text] [Related]
10. Synthesis and receptor binding affinity of cholecystokinin receptor ligands: 2-and 1-indolyl derivatives of PD134308.
Araldi G; Donati D; Oliosi B; Ursini A; van Amsterdam F; Natalini B; Pellicciari R; Tarzia G
Farmaco; 1996 Jul; 51(7):471-6. PubMed ID: 8765669
[TBL] [Abstract][Full Text] [Related]
11. Problems when withdrawing corticosteroids.
Drug Ther Bull; 1987 Sep; 25(19):73-5. PubMed ID: 3665733
[No Abstract] [Full Text] [Related]
12. Exogenous testosterone attenuates the integrated central stress response in healthy young women.
Hermans EJ; Putman P; Baas JM; Gecks NM; Kenemans JL; van Honk J
Psychoneuroendocrinology; 2007; 32(8-10):1052-61. PubMed ID: 17904297
[TBL] [Abstract][Full Text] [Related]
13. The combined dexamethasone-suppression/CRH-stimulation test in alcoholics during and after acute withdrawal.
Hundt W; Zimmermann U; Pöttig M; Spring K; Holsboer F
Alcohol Clin Exp Res; 2001 May; 25(5):687-91. PubMed ID: 11371718
[TBL] [Abstract][Full Text] [Related]
14. [Corticosteroid therapy].
Pentikäinen PJ
Duodecim; 1986; 102(22):1690-9. PubMed ID: 3803259
[No Abstract] [Full Text] [Related]
15. Hypothalamic-pituitary-adrenocortical axis activity as a potential predictor for withdrawal symptoms in addiction to flupirtine, a nonopiate analgesic.
Hennings JM; Ising M; Klengel T; Knop M; Rosenhagen MC
J Clin Psychopharmacol; 2014 Dec; 34(6):e6-8. PubMed ID: 24633005
[No Abstract] [Full Text] [Related]
16. Comparable effects of inhaled fluticasone propionate and budesonide on the HPA-axis in adult asthmatic patients.
Ringdal N; Lundbäck B; Alton M; Rak S; Eivindson A; Bratten G; Kjaersgaard P
Respir Med; 2000 May; 94(5):482-9. PubMed ID: 10868712
[TBL] [Abstract][Full Text] [Related]
17. Prenatal opiate withdrawal activates the chick embryo hypothalamic pituitary-adrenal axis and dilates vitelline blood vessels via serotonin(2) receptors.
Schrott LM; Baumgart MI; Zhang X; Sparber SB
J Pharmacol Exp Ther; 2002 Oct; 303(1):257-64. PubMed ID: 12235259
[TBL] [Abstract][Full Text] [Related]
18. Acute effects of megestrol on the hypothalamic-pituitary-adrenal axis.
Raedler TJ; Jahn H; Goedeken B; Gescher DM; Kellner M; Wiedemann K
Cancer Chemother Pharmacol; 2003 Dec; 52(6):482-6. PubMed ID: 13680163
[TBL] [Abstract][Full Text] [Related]
19. The role of corticotropin-releasing factor in drug addiction.
Sarnyai Z; Shaham Y; Heinrichs SC
Pharmacol Rev; 2001 Jun; 53(2):209-43. PubMed ID: 11356984
[TBL] [Abstract][Full Text] [Related]
20. Stimulation of the hypothalamo-pituitary-adrenal axis in the rat by three selective type-4 phosphodiesterase inhibitors: in vitro and in vivo studies.
Kumari M; Cover PO; Poyser RH; Buckingham JC
Br J Pharmacol; 1997 Jun; 121(3):459-68. PubMed ID: 9179387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
